fbpx

Larvol Omni

Discover the next generation of KOL and drug tracking with Larvol Omni
Request A Demo

Never miss an opportunity to engage

Work seamlessly between your mobile and desktop devices

Get notifications and stay up-to-date on all the KOLs and drugs you follow

Collaborate with your team or work individually

Key Features

Take Notes

Contact Info

KOL Analytics

Push Notifications

Sunshine Data

Bookmark Content

larvol-thought-leader

Clyde W Yancy, MD

Northwestern University Feinberg School of Medicine, Chicago, IL, US

Interventional Cardiology Conference 2019

03/02/2019 – 03/05/2019, Washington, DC, USA

“The conference serves as a forum for physician and health-care professional education about new cardiovascular technology and interventional procedures in the field. The meeting is actually several conferences at once, with tracks including CRT Valve & Structural, CRT Endovascular, Technology & Innovation, Atherosclerosis & Research, and Nurses & Technologists.”

Medicine Grand Rounds

03/06/2019, Tucson, AZ, USA

“The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Topics include diagnosing a variety of internal medicine illnesses understanding more clearly advances in therapy, and becoming truly professional physicians.”
Online CME

Heart Failure with Preserved Ejection Fraction in Women

(PubMed), 01/15/2019

Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly in women. Comorbidities, including older age, obesity, diabetes mellitus, hypertension, and hyperlipidemia, are risk factors and define phenotypic profiles of HFpEF in women.
Journal Clinical

Intensive Blood Pressure Control Does Not Decrease Dementia Risk

(PracticeUpdate), 02/16/2019

The stunning results of SPRINT substantially influenced the latest guidelines to treat hypertension. Incontrovertible evidence now supports goal blood pressure reduction to 120/80 mm Hg in those patients deemed at higher cardiovascular risk as a means to reduce total mortality, and, uniquely, to prevent heart failure.
Online Posting

IMPROVE-HF: IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting

P=N/A

Completed

AC6 Gene Transfer for CHF

P1/2

Completed

A new and potentially important phenotype of heart failure emerges

Clyde Yancy, MD, @NMHheartdoc, 02/20/2019

“A new and potentially important phenotype of heart failure emerges; an evolving database suggests that HF with midrange EF is associated with better outcomes. No yet identified therapies. Continue GDMT. Need to discover pathways of recovery.”
Tweet

Leading the way for a bold future

Clyde Yancy, MD, @NMHheartdoc, 02/22/2019

“Leading the way for a bold future; Masters level training in Artificial Intelligence- new language, new tool and new opportunities. Looking forward to seeing the best of the best apply and work with @NMCardioVasc @JamesDThomasMD1 @NorthwesternMed @NUFeinbergMed”
Tweet

Why Track KOLs?

IMPROVE UNDERSTANDING

We know how valuable the opinions of KOLs are. Monitoring KOL activity allows for a better understanding of how the physician community receives your messages and lets you identify concerns and education opportunities.

DISCOVER ENGAGEMENT OPPORTUNITIES

Tracking KOLs ensures that your products are included in relevant discussions. Knowing where a KOL is going to be – which conferences, symposiums, and CME events they’ll be attending or presenting at – allows for crucial opportunities to engage with a KOL and the other physicians who follow them. Our customers explain how valuable it is to see that a KOL is publicly discussing mechanisms of action that they’re working with and creates an opportunity to reach out and establish a key relationship.

TRACKING vs MAPPING

Mapping is the process of identifying thought leaders / KOLs that are influential in your area and their relationships. Tracking comes after mapping and involves monitoring the ongoing activity (publications, opinions, and events) of specific KOLs to better understand the evolution of their positioning. Tracking also ensures that you are up-to-date with the perspectives of your KOLs and that you can identify opportunities to engage with them.

Our Complete KOL and Drug Monitoring Solution Includes

News

Publications, trial updates, news, media mentions – any news item that isn’t an event or a tweet.

Events

Calendar listing of upcoming conferences, symposiums, lectures, CME and other events that a KOL is attending or speaking at.

Social Media

Twitter provides a direct line to your key influencers’ reactions. You can find tweets authored by the KOL as well as mentions of the KOL by others.

Clinical Trials

Updates on the latest clinical trials associated with your KOLs, covering both clinicaltrials.gov and EudraCT. Includes changes such as enrollment status, new data, discontinuations and more.

Request A Demo

Enter your information to be contacted by our sales team about Larvol Omni, to schedule a demo, or subscribe.

By signing up for a free report or trial, you agree to our Privacy Policy
Yes, I would like to subscribe to updates from Larvol